Ask sales for the lot-numbered COA. Net peptide content, RP-HPLC, ESI-MS, or other results appear only when they are part of that batch's agreed analytical scope.

Batch COA records net peptide content when included in the agreed specification.

Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →

On reading HPLC traces. Read →

SS-31 (Elamipretide)

Name: SS-31 (Elamipretide)
Brand: Lyochem
SKU: ss-31

Mitochondrial-targeted peptide

≥ 99.0%CAS 736992-21-5Mitochondrial & Energy

Lyochem primary owner

SS-31 (Elamipretide) for research-standard qualification and analytical packet review

This Lyochem page is the primary SEO owner for research labs, CROs, and method-development teams qualifying SS-31 (Elamipretide) as a documented research-standard lot. The page should answer whether the buyer can review HPLC purity, identity confirmation, lot continuity, stability handling, and assay-fit documentation before ordering.

Use this page when the buyer needs an analytical packet, sequence or identity evidence, reference-lot continuity, or method-development support.
Request the analytical packet when the decision is assay replication, internal method transfer, or research-vendor qualification.
Pharmacy release-documentation procurement and broad distributor / OEM sourcing where catalog economics dominate are separate buying contexts served elsewhere.

Overview

A synthetic cationic-aromatic tetrapeptide, SS-31 (Elamipretide, Bendavia, MTP-131) carries the sequence D-Arg-Dmt-Lys-Phe-NH₂, in which Dmt denotes 2',6'-dimethyl-L-tyrosine. Its alternating charge-and-aromatic motif — the defining feature of the Szeto-Schiller cell-permeable, mitochondria-targeted class — lets the peptide accumulate passively across the inner mitochondrial membrane along the negative membrane potential. There it associates with cardiolipin and shields that lipid from peroxidation; preserving cardiolipin in turn stabilizes cristae architecture and OXPHOS supercomplex function. This mechanism underlies the molecule's clinical-development work in mitochondrial dysfunction disorders such as Barth syndrome and primary mitochondrial myopathies, and in acute-injury settings including ischemia-reperfusion injury and contrast-induced nephropathy. Lyochem supplies SS-31 acetate as a lyophilized research standard with a ≥99.0% HPLC catalogue target. Ask sales for the matching batch COA; it states the identity and purity work actually completed. LC-MS/MS, counter-ion, water, or other expanded evidence is included only when available or required by an agreed written scope. Three fill sizes (5, 10, 50 mg) span standard research needs.

Applications & buyer fit

What research workflows this standard is sourced for

Mitochondrial-targeted peptides — MOTS-c, SS-31 (Elamipretide) — and the mitochondrial-targeting small-molecule reagents (NAD+, AICAR, 5-Amino-1MQ, SLU-PP-332) ship to research labs studying OXPHOS, ROS biology, sirtuin-mediated deacetylation, and mitochondrial dysfunction in disease models. The lipophilic / cationic character that drives mitochondrial accumulation also makes some peptides oxidation-prone in solution; working stocks should be prepared fresh or held at −80 °C when the workflow permits.

Research-buyer fit

Academic Laboratories

Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.

Biotech R&D Groups

Preclinical biotech and pharmaceutical discovery teams sourcing characterized peptides for receptor-pharmacology, screening, and method-development campaigns.

Standard lot documentation

Per-lot Certificate of Analysis
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Sample COA on request
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Research Use Only · B2B supply
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.

Specifications

CAS: 736992-21-5
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 5 mg – 50 mg
Packaging: 10 vials/box · base pack (multiples of 10)
Half-life: ≈ 0.5-1 hour
MOQ: On request
Lead time: 14–21 days
Storage: 2–8°C, protect from light

Documentation available on request

Lot-specific Certificate of Analysis (CoA)
RP-HPLC chromatogram with peak integration
ESI-MS identity confirmation (±0.5 Da)
Sequence verification by LC-MS/MS
Water content by Karl Fischer
SDS / MSDS
Oxidative-stability series in solution
Bacterial endotoxin (LAL) on request
−80 °C working-stock handling guidance

Independent analytical report

Product- and strength-matched first-page previews are shown separately from the Batch COA. Contact sales with the report number for the complete high-resolution file.

Third-party testView report record →

SS-31

50 mg · HPLC / MS

SS50-20260806S9397

Third-party testing in Tianjin

Independent HPLC and mass-spectrometry reports from Qorix , the professional, authoritative third-party analytical laboratory at tjqxgd.com, affiliated with the Tianjin International Joint Academy of Biomedicine.

Regulatory note

Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form and not labelled for human administration. Working stocks of cationic mitochondrial peptides (SS-31 in particular) should be prepared fresh or held at −80 °C when the workflow permits.

Selected literature

Thompson WR, Hornby B, Manuel R, Bradley E, Laux J, Carr J, Vernon HJ. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471-478.
Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):101138.
Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238-e252.
Sabbah HN, Gupta RC, Kohli S, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 2017;10(8):e004389.
Ehlers JP, Khanani AM, Wykoff CC, et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation. Ophthalmol Sci. 2025;5(1):100621.
Chavez JD, Tang X, Campbell MD, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci U S A. 2020;117(26):15363-15373.

Frequently asked questions

How is Lyochem's SS-31 documented as the amidated D-Arg-Dmt-Lys-Phe sequence?▾

Ask sales for the batch COA matched to the offered or supplied SS-31 lot. It records the identity work actually completed. If a written qualification procedure requires LC-MS/MS fragment coverage to read residue order, agree that optional scope before quotation rather than assuming it is included because the supplier is new.

What counter-ion and water-content data should accompany an SS-31 reference standard, and why do they matter for assay dosing?▾

Review the applicable batch COA for the supplied form and any content, counter-ion, or water results actually reported. Where a quantitative workflow requires those items, include them in the agreed analytical scope so calculations use the recorded lot values rather than a catalogue assumption.

Related peptides

Buyers who view SS-31 (Elamipretide) also ask about:

16-mer

MOTS-c (Human)

≥99.0%

Mitochondrial-derived peptide

CAS: 1627580-64-6
Vial: 10 mg–40 mg

MOQ on requestView details →

See full catalog

SS-31 (Elamipretide)

Mitochondrial-targeted peptide

≥ 99.0%CAS 736992-21-5Mitochondrial & Energy

Lyochem primary owner

SS-31 (Elamipretide) for research-standard qualification and analytical packet review

Use this page when the buyer needs an analytical packet, sequence or identity evidence, reference-lot continuity, or method-development support.
Request the analytical packet when the decision is assay replication, internal method transfer, or research-vendor qualification.
Pharmacy release-documentation procurement and broad distributor / OEM sourcing where catalog economics dominate are separate buying contexts served elsewhere.

Overview

Applications & buyer fit

What research workflows this standard is sourced for

Research-buyer fit

Academic Laboratories

Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.

Biotech R&D Groups

Preclinical biotech and pharmaceutical discovery teams sourcing characterized peptides for receptor-pharmacology, screening, and method-development campaigns.

Standard lot documentation

Per-lot Certificate of Analysis
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Sample COA on request
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Research Use Only · B2B supply
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.

Specifications

CAS: 736992-21-5
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 5 mg – 50 mg
Packaging: 10 vials/box · base pack (multiples of 10)
Half-life: ≈ 0.5-1 hour
MOQ: On request
Lead time: 14–21 days
Storage: 2–8°C, protect from light

Documentation available on request

Lot-specific Certificate of Analysis (CoA)
RP-HPLC chromatogram with peak integration
ESI-MS identity confirmation (±0.5 Da)
Sequence verification by LC-MS/MS
Water content by Karl Fischer
SDS / MSDS
Oxidative-stability series in solution
Bacterial endotoxin (LAL) on request
−80 °C working-stock handling guidance

Independent analytical report

Product- and strength-matched first-page previews are shown separately from the Batch COA. Contact sales with the report number for the complete high-resolution file.

Third-party testView report record →

SS-31

50 mg · HPLC / MS

SS50-20260806S9397

Third-party testing in Tianjin

Regulatory note

Selected literature

Thompson WR, Hornby B, Manuel R, Bradley E, Laux J, Carr J, Vernon HJ. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471-478.
Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):101138.
Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238-e252.
Sabbah HN, Gupta RC, Kohli S, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 2017;10(8):e004389.
Ehlers JP, Khanani AM, Wykoff CC, et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation. Ophthalmol Sci. 2025;5(1):100621.
Chavez JD, Tang X, Campbell MD, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci U S A. 2020;117(26):15363-15373.

Frequently asked questions

How is Lyochem's SS-31 documented as the amidated D-Arg-Dmt-Lys-Phe sequence?▾

What counter-ion and water-content data should accompany an SS-31 reference standard, and why do they matter for assay dosing?▾

Related peptides

Buyers who view SS-31 (Elamipretide) also ask about:

16-mer

MOTS-c (Human)

≥99.0%

Mitochondrial-derived peptide

CAS: 1627580-64-6
Vial: 10 mg–40 mg

MOQ on requestView details →

See full catalog